Several studies have demonstrated that soy isoflavone (SIF) supplementation can improve aspects of cognitive function. However, these findings remain controversial. We aimed to quantify the effects of SIF supplementation on improving cognitive function in postmenopausal women.
Databases and relevant Websites were searched for relevant studies up to March 2014. Two reviewers independently verified all potentially suitable randomized controlled trials (RCTs) using inclusion and exclusion criteria, and the quality of identified RCTs was assessed using the Jadad scale and the Risk of Bias Tool from the “Cochrane handbook for systematic reviews of interventions.” Any disagreement on study quality or data extraction was resolved by consensus; a third reviewer was consulted if needed. Standardized mean differences (SMDs) in cognitive function test scores were calculated between SIF-treated and placebo-treated groups.
We conducted a meta-analysis of 10 placebo-controlled RCTs of SIF supplementation (1,024 participants; treatment duration of 6 wk to 30 mo). The overall SMD in summary cognitive function test scores (0.08) was statistically significant (95% CI, 0.02-0.15; P = 0.014). The summary SMD for visual memory (0.10) was statistically significant (95% CI, 0.02-0.18; P = 0.016). In subgroup analyses, the statistically significant SMDs were as follows: 0.12 (95% CI, 0-0.25; P = 0.044) for non-US countries; 0.16 (95% CI, 0.05-0.28; P = 0.004) for mean age younger than 60 years; and 0.15 (95% CI, 0.03-0.27; P = 0.011) for treatment duration less than 12 months.
SIF supplementation seems to have a positive effect on improving summary cognitive function and visual memory in postmenopausal women. There may be a critical window of opportunity in initiating SIF use at an earlier age in postmenopausal women, and geography and treatment duration seem to be factors influencing the effects of SIF supplementation. All individuals in the included studies should be followed up to observe the incidence rates of Alzheimer’s disease and dementia, and future studies should report any adverse effects of SIF supplementation.
Supplemental digital content is available in the text.
From the 1Department of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China; 2Chongqing Key Laboratory of Neurobiology, Chongqing, China; 3Institute of Neuroscience, Chongqing Medical University, Chongqing, China; and 4Department of Neurology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
Received February 19, 2014; revised and accepted May 7, 2014.
P.-F.C. and J.-J.C. contributed equally to this manuscript.
Funding/support: This study was sponsored by the National Basic Research Program of China (973 program, grant 2009CB918300; general program, grant H0906).
Financial disclosure/conflicts of interest: None reported.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Website (www.menopause.org).
Address correspondence to: Peng Xie, MD, Department of Neurology,The First Affiliated Hospital, Chongqing Medical University, 1 Yixueyuan Road, Yuzhong District, Chongqing 400016, China. E-mail: firstname.lastname@example.org